HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Purinergic P2 Receptors (ADP Receptor)

Subscribe to New Research on Purinergic P2 Receptors

A class of cell surface receptors for PURINES that prefer ATP or ADP over ADENOSINE. P2 purinergic receptors are widespread in the periphery and in the central and peripheral nervous system.

Also Known As:

ADP Receptor; Purinergic P2 Receptor; Receptors, Purinergic P2; ATP Receptor; P2 Purinoceptor; Receptor, Purinergic P2; P2 Receptor, Purinergic; P2 Receptors, Purinergic; Purinoceptor, P2; Purinoceptors, P2; Receptor, ADP; Receptor, ATP; ADP Receptors; ATP Receptors; P2 Purinoceptors; Receptors, ADP; Receptors, ATP

Networked: 246 relevant articles (8 outcomes, 30 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Proteins: 90489
  - Membrane Proteins: 5300
    - Cell Surface Receptors: 753

Experts

1.	Inoue, Kazuhide: 19 articles (01/2013 - 08/2003)
2.	Tsuda, Makoto: 14 articles (11/2012 - 08/2003)
3.	Koizumi, Schuichi: 6 articles (06/2005 - 08/2003)
4.	Erlinge, David: 5 articles (01/2011 - 12/2004)
5.	Peterson, Eric D: 4 articles (12/2015 - 08/2014)
6.	Wang, Tracy Y: 4 articles (12/2015 - 08/2014)
7.	Idzko, Marco: 4 articles (12/2012 - 03/2007)
8.	Tozaki-Saitoh, Hidetoshi: 4 articles (11/2012 - 09/2007)
9.	Heemskerk, Johan W M: 4 articles (04/2007 - 03/2003)
10.	Effron, Mark B: 3 articles (12/2015 - 07/2015)

Related Diseases

1.	Myocardial Infarction 12/01/2015 - "In-hospital ADP receptor inhibitor switching occurs in more than one in 10 myocardial infarction patients in contemporary practice. " 07/21/2015 - "We compared outcomes of 10 213 patients with myocardial infarction who underwent percutaneous coronary intervention and were discharged on dual-antiplatelet therapy at 228 US hospitals in the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study from 2010 to 2012. " 07/01/2015 - "Early Medication Nonadherence After Acute Myocardial Infarction: Insights into Actionable Opportunities From the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study." 12/01/2009 - "Inhibition of the P2Y12 ADP-receptor with oral antiplatelet agents given to patients undergoing primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) is associated with improved outcomes, but this strategy is limited by the time required for maximal antiplatelet effect after administration. " 08/01/2014 - "Although randomized clinical trials have compared clopidogrel with higher potency ADP receptor inhibitors (ADPris) among patients with myocardial infarction, little is known about the frequency and factors associated with switching between ADPris in clinical practice. "
2.	Stroke (Strokes) 01/01/2003 - "In a meta-analysis performed by the Cochrane Stroke Group, ADP-receptor antagonist therapy significantly reduced the odds of a serious vascular event (stroke, MI or vascular death) by 9% (2p = 0.01) and of any stroke by 12%. " 10/15/1998 - "Ticlopidine also belongs to the same class of ADP receptor inhibitors and is extensively used for stroke prevention. " 10/01/2003 - "Although clopidogrel is widely used in patients with acute coronary syndromes and ischemic stroke, the ability of this novel ADP-receptor antagonist to inhibit platelet function in patients with CHF is unknown. " 01/01/2011 - "The platelet inhibitors blocking the ADP-receptor P2Y(12) reduce myocardial infarction, stroke, and mortality in patients with cardiovascular disease. " 08/01/2000 - "Clopidogrel is an ADP receptor antagonist that is indicated for the reduction of atherosclerotic events including myocardial infarction, ischaemic stroke and vascular death in patients with atherosclerosis manifested by recent stroke, myocardial infarction or established peripheral vascular disease. "
3.	Atherosclerosis 11/19/2002 - "These findings indicate for the first time a role for the UTP/ATP receptor, P2Y2, in development of intimal hyperplasia associated with atherosclerosis and restenosis." 08/01/2000 - "Clopidogrel is an ADP receptor antagonist that is indicated for the reduction of atherosclerotic events including myocardial infarction, ischaemic stroke and vascular death in patients with atherosclerosis manifested by recent stroke, myocardial infarction or established peripheral vascular disease. " 11/01/2015 - "VD deficiency decreased plasma high-density lipoprotein levels, expression of liver X receptors, ATP-binding membrane cassette transporter A1, and ATP-binding membrane cassette transporter G1 and promoted cholesterol accumulation and atherosclerosis in hypercholesterolemic microswine. " 05/01/2004 - "Clopidogrel is an ADP receptor antagonist that is superior to acetylsalicylic acid (ASA) for the prevention of ischaemic stroke, myocardial infarction and vascular death in patients with symptomatic atherosclerosis. " 01/01/1999 - "Clopidogrel, a new platelet ADP receptor antagonist, is more effective than aspirin in reducing the risk of subsequent vascular ischemic events in patients with a broad spectrum of symptomatic atherosclerosis (recent ischemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease). "
4.	Thrombosis (Thrombus) 01/01/2013 - "The platelet ADP receptor P2Y12 amplifies the initial hemostatic responses activated by a variety of platelet agonists and stabilizes platelet aggregation, playing a crucial role in granule secretion, integrin activation and thrombus formation. " 01/01/2013 - "Platelet ADP receptor P2Y(12) is well studied and recognized as a key player in platelet activation, hemostasis and thrombosis. " 04/01/2002 - "Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood." 03/01/2003 - "In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability." 07/01/2013 - "Our data support the hypothesis that the use of ADP receptor inhibitors, in addition to aspirin, might be considered in the prevention of thrombosis in these conditions, by allowing a more complete inhibition of platelet functions."
5.	Acute Coronary Syndrome 07/01/2015 - "We assessed 7425 acute MI patients treated with percutaneous coronary intervention at 216 US hospitals participating in TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) between April 2010 and May 2012. " 11/01/2001 - "The long-term use of blockers of the platelet ADP receptor in acute coronary syndromes." 07/21/2015 - "We compared outcomes of 10 213 patients with myocardial infarction who underwent percutaneous coronary intervention and were discharged on dual-antiplatelet therapy at 228 US hospitals in the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study from 2010 to 2012. " 07/01/2015 - "Early Medication Nonadherence After Acute Myocardial Infarction: Insights into Actionable Opportunities From the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study." 07/01/2013 - "Immediate blocking of platelet aggregation in high-risk acute coronary syndrome patients by intracoronary abciximab bolus-only administration and bridging to prolonged inhibition via oral blockade of ADP receptors effectively inhibited overall platelet reactivity for at least 48 h, questioning the value of continuous abciximab infusion. "

Related Drugs and Biologics

1.	clopidogrel (Plavix)
2.	Aspirin (Acetylsalicylic Acid)
3.	Adenosine Diphosphate (ADP)
4.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
5.	Adenosine Triphosphate (ATP)
6.	Purinergic P2 Receptors (ADP Receptor)
7.	Adenosine
8.	Ticlopidine (Ticlid)
9.	prasugrel
10.	Glutamic Acid (Glutamate)

Related Therapies and Procedures

1.	Stents
2.	Therapeutics
3.	Resuscitation
4.	Laparotomy
5.	Spinal Injections